$BBIO

BridgeBio Pharma, Inc.

BridgeBio Pharma is a commercial-stage biopharmaceutical company that discovers, develops and commercializes medicines for patients with genetic diseases. Its portfolio includes Attruby, an approved oral treatment for transthyretin amyloid cardiomyopathy, marketed in the United States; the same medicine is sold as Beyonttra in markets served by partners including Bayer in Europe and Alexion in Japan. Other approved products include Nulibry, whose global rights BridgeBio sold to Sentynl Therapeutics, and Truseltiq, which is no longer commercially available. Development programs include infigratinib for achondroplasia, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and encaleret for autosomal dominant hypocalcemia type 1. BridgeBio earns money through product sales, licensing and services, and royalties, and works with strategic partners to commercialize products in some markets. BridgeBio is headquartered in Palo Alto, California.

AlphAI earnings readSecond Quarter 2026 · AUG 10BridgeBio Reports Second Quarter 2026 Financial Results and Corporate UpdatesVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
2
0
—
$146K
Apuli Maricel
100%
See all $BBIO insider activity →

BridgeBio Pharma, Inc. (BBIO) Reports Acoramidis Reduced First Heart Failure Event Risk 45%

BridgeBio Pharma (BBIO) reported that acoramidis reduced the risk of a first heart failure event by 45% versus placebo in the ATTRibute-CM trial, with benefits observed within the first month. Real-world data from Germany showed a 23% lower risk of ODI versus tafamidis. The drug also demonstrated durable reduction in heart failure mortality through 54 months and stable kidney function in CKD stage 4 patients.

BBIO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BBIO (BridgeBio Pharma, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.

Recent BBIO coverage spans financial news, regulation and earnings.

In the last 30 days, BBIO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($146K). The most active reporter was Apuli Maricel, Chief Accounting Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving BBIO

AlphAI scores every news story that mentions BBIO with an AI model for sentiment and relevance, and aggregates insider trades from BridgeBio Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BBIO

Score

BridgeBio Pharma, Inc. (BBIO) Reports Acoramidis Reduced First Heart Failure Event Risk 45%

BridgeBio Pharma (BBIO) reported that acoramidis reduced the risk of a first heart failure event by 45% versus placebo in the ATTRibute-CM trial, with benefits observed within the first month. Real-world data from Germany showed a 23% lower risk of ODI versus tafamidis. The drug also demonstrated durable reduction in heart failure mortality through 54 months and stable kidney function in CKD stage 4 patients.

A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End

Five biotech companies have FDA target action dates between Nov. 27 and Dec. 27, 2026, for various drug applications. BridgeBio (BBIO) reports $353.2M Q3 revenue, Vertex (VRTX) raises 2026 revenue guidance, Gilead (GILD) reports 13% sales growth, Viatris (VTRS) reports flat Q3 revenue, and Praxis (PRAX) updates on NDA progress. Each company's application is under review, with no guaranteed outcomes.

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

Related tickers